Want to see VASO full AI Analyst Report?
VASO Stock Chart & Stats
$0.29
<$0.01(3.90%)
At close: 4:00 PM EDT
$0.29
<$0.01(3.90%)
Day’s Range― - ―
52-Week Range$0.11 - $0.32
Previous CloseN/A
Volume43.05K
Average Volume (3M)263.26K
Market Cap
$50.86M
Enterprise Value-$2.82
Total Cash (Recent Filing)$38.29M
Total Debt (Recent Filing)$1.79M
Price to Earnings (P/E)19.2
Beta0.69
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding176,018,040
10 Day Avg. Volume119,517
30 Day Avg. Volume263,261
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)1.04
Price to Sales (P/S)0.35
P/FCF Ratio3.68
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageA conservatively positioned balance sheet reduces refinancing risk and preserves financial flexibility. Low leverage should help Vaso absorb operating volatility and maintain strategic options over the next several quarters.
Cash ConversionPositive operating and free cash flow, with TTM free cash flow above net income, indicates that reported earnings are converting into liquidity. This supports ongoing operations and improves resilience despite uneven earnings performance.
Portfolio RefocusThe NetWolves divestiture simplifies Vaso's corporate structure and removes that business from consolidated operations. The transaction may allow management to focus resources on the remaining portfolio while adding cash to the corporate balance sheet.
Bears Say
Revenue ContractionRecent revenue contraction signals weaker demand, customer activity, or business scale than in the prior period. Without a return to sustainable growth, lower revenue can limit operating leverage and make margin recovery more difficult.
Compressed ProfitabilityProfitability has weakened materially from the 2022–2023 peak, while operating performance remains inconsistent. Thin recent margins leave less protection against cost pressure and raise questions about the durability of future earnings.
Volatile Free Cash FlowAlthough cash flow is currently positive, sharp year-to-year swings reduce confidence in its predictability. Volatility may reflect uneven working-capital movements or investment timing, complicating planning and making sustainable cash generation harder to assess.
Vaso News
VASO FAQ
What was Vaso Corp.’s price range in the past 12 months?
Vaso Corp. lowest stock price was $0.10 and its highest was $0.32 in the past 12 months.
What is Vaso Corp.’s market cap?
Vaso Corp.’s market cap is $50.86M.
When is Vaso Corp.’s upcoming earnings report date?
Vaso Corp.’s upcoming earnings report date is Nov 16, 2026 which is in 72 days.
How were Vaso Corp.’s earnings last quarter?
Vaso Corp. released its earnings results on Aug 14, 2026. The company reported $0.003 earnings per share for the quarter.
Is Vaso Corp. overvalued?
According to Wall Street analysts Vaso Corp.’s price is currently Overvalued.
Does Vaso Corp. pay dividends?
Vaso Corp. does not currently pay dividends.
What is Vaso Corp.’s EPS estimate?
Vaso Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaso Corp. have?
Vaso Corp. has 176,018,040 shares outstanding.
What happened to Vaso Corp.’s price movement after its last earnings report?
Vaso Corp. reported an EPS of $0.003 in its last earnings report. Following the earnings report the stock price went up 3.077%.
Which hedge fund is a major shareholder of Vaso Corp.?
Currently, no hedge funds are holding shares in VASO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vaso Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
144.88%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.03%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Vaso Corp.
Vaso Corporation is a diversified enterprise engaged in both the healthcare equipment and information technology industries, serving markets within the United States and globally. The company's operations are structured across three primary divisions: 1. IT (Information Technology): This segment is dedicated to providing specialized IT solutions for the healthcare sector, alongside managed network technology services. Its services encompass managed diagnostic imaging applications, network infrastructure management, network transport, and comprehensive cybersecurity solutions. 2. Professional Sales Service: This division primarily focuses on the distribution of capital medical equipment manufactured by General Electric Healthcare (GEHC) to mid-sized healthcare providers. Its offerings include GEHC diagnostic imaging hardware, associated service contracts, training programs, and financial services facilitated by both GEHC and external partners. 3. Equipment: This segment concentrates on the development, manufacturing, sales, and servicing of its own proprietary medical devices. Its product portfolio features the Biox series, which includes Holter monitors and ambulatory blood pressure recorders; the ARCS series software for analyzing, reporting, and communicating ECG and blood pressure data; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation (EECP) therapy systems, used for non-invasive, outpatient treatment of ischemic heart disease. Founded in 1987, the company was originally named Vasomedical, Inc. before officially rebranding as Vaso Corporation in November 2016. Vaso Corporation maintains its corporate headquarters in Plainview, New York.
Technical Analysis
Healthcare Triangle
―
HeartBeam
―
VSee Health
―
BullFrog AI Holdings, Inc.
―
Mangoceuticals, Inc.
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.04% Other Institutional Investors
99.96% Public Companies and
Individual Investors